Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells

R. Silvestrini, N. Zaffaroni, R. Villa, L. Orlandi, A. Costa

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with 300 μM lonidamine significantly potentiated the activity of a 1-hr cisplatin treatment in both cell lines. In particular, the cisplatin IC50 value was reduced 4-fold in the sensitive line and 5-fold in the resistant line. Flow cytometric analysis showed that, in the resistant cell line, lonidamine alone did not affect cell kinetics, but when given after cisplatin it was able to transform the temporary G2 + M cell accumulation induced by the alkylating agent to a persistent block in S/G2 + M. In the A2780/cp8 cell line, lonidamine was also able to significantly enhance the accumulation of cisplatin-induced DNA interstrand cross-links. Our results suggest that lonidamine can positively modulate the anti-tumor activity of cisplatin in ovarian cancer cells and also indicate that the drug is potentially useful in combination therapy including the alkylating agent for ovarian cancer patients.

Original languageEnglish
Pages (from-to)813-817
Number of pages5
JournalInternational Journal of Cancer
Volume52
Issue number5
DOIs
Publication statusPublished - 1992

Fingerprint

Ovarian Neoplasms
Cisplatin
Alkylating Agents
Cell Line
Inhibitory Concentration 50
lonidamine
Acids
DNA
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. / Silvestrini, R.; Zaffaroni, N.; Villa, R.; Orlandi, L.; Costa, A.

In: International Journal of Cancer, Vol. 52, No. 5, 1992, p. 813-817.

Research output: Contribution to journalArticle

Silvestrini, R. ; Zaffaroni, N. ; Villa, R. ; Orlandi, L. ; Costa, A. / Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. In: International Journal of Cancer. 1992 ; Vol. 52, No. 5. pp. 813-817.
@article{abcc32856bdb4671b8e213a1d2bc07ab,
title = "Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells",
abstract = "The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with 300 μM lonidamine significantly potentiated the activity of a 1-hr cisplatin treatment in both cell lines. In particular, the cisplatin IC50 value was reduced 4-fold in the sensitive line and 5-fold in the resistant line. Flow cytometric analysis showed that, in the resistant cell line, lonidamine alone did not affect cell kinetics, but when given after cisplatin it was able to transform the temporary G2 + M cell accumulation induced by the alkylating agent to a persistent block in S/G2 + M. In the A2780/cp8 cell line, lonidamine was also able to significantly enhance the accumulation of cisplatin-induced DNA interstrand cross-links. Our results suggest that lonidamine can positively modulate the anti-tumor activity of cisplatin in ovarian cancer cells and also indicate that the drug is potentially useful in combination therapy including the alkylating agent for ovarian cancer patients.",
author = "R. Silvestrini and N. Zaffaroni and R. Villa and L. Orlandi and A. Costa",
year = "1992",
doi = "10.1002/ijc.2910520524",
language = "English",
volume = "52",
pages = "813--817",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells

AU - Silvestrini, R.

AU - Zaffaroni, N.

AU - Villa, R.

AU - Orlandi, L.

AU - Costa, A.

PY - 1992

Y1 - 1992

N2 - The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with 300 μM lonidamine significantly potentiated the activity of a 1-hr cisplatin treatment in both cell lines. In particular, the cisplatin IC50 value was reduced 4-fold in the sensitive line and 5-fold in the resistant line. Flow cytometric analysis showed that, in the resistant cell line, lonidamine alone did not affect cell kinetics, but when given after cisplatin it was able to transform the temporary G2 + M cell accumulation induced by the alkylating agent to a persistent block in S/G2 + M. In the A2780/cp8 cell line, lonidamine was also able to significantly enhance the accumulation of cisplatin-induced DNA interstrand cross-links. Our results suggest that lonidamine can positively modulate the anti-tumor activity of cisplatin in ovarian cancer cells and also indicate that the drug is potentially useful in combination therapy including the alkylating agent for ovarian cancer patients.

AB - The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with 300 μM lonidamine significantly potentiated the activity of a 1-hr cisplatin treatment in both cell lines. In particular, the cisplatin IC50 value was reduced 4-fold in the sensitive line and 5-fold in the resistant line. Flow cytometric analysis showed that, in the resistant cell line, lonidamine alone did not affect cell kinetics, but when given after cisplatin it was able to transform the temporary G2 + M cell accumulation induced by the alkylating agent to a persistent block in S/G2 + M. In the A2780/cp8 cell line, lonidamine was also able to significantly enhance the accumulation of cisplatin-induced DNA interstrand cross-links. Our results suggest that lonidamine can positively modulate the anti-tumor activity of cisplatin in ovarian cancer cells and also indicate that the drug is potentially useful in combination therapy including the alkylating agent for ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0026446255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026446255&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910520524

DO - 10.1002/ijc.2910520524

M3 - Article

VL - 52

SP - 813

EP - 817

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -